BMO Capital analyst Etzer Darout downgraded ImmunoGen (IMGN) to Market Perform from Outperform with a price target of $31, up from $26, after the company agreed to be acquired by AbbVie (ABBV) for $31.26 per share in cash. The firm sees low ImmunoGen pipeline risks in terms of the deal closing given that the pre-deal price implied little pipeline credit and it expects Elahere to continue to meet or exceed sales expectations in the near term.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IMGN: